## Raisa S Pompe

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6097756/publications.pdf

Version: 2024-02-01

60 1,194 20 31 papers citations h-index g-index

60 60 60 1880 all docs docs citations times ranked citing authors

#	Article	lF	CITATIONS
1	Anesthetic Technique (Spinal vs. General Anesthesia) in Holmium Laser Enucleation of the Prostate: Retrospective Analysis of Procedural and Functional Outcomes among 1,159 Patients. Urologia Internationalis, 2023, 107, 336-343.	1.3	2
2	Salvage Radiotherapy versus Observation for Biochemical Recurrence following Radical Prostatectomy for Prostate Cancer: A Matched Pair Analysis. Cancers, 2022, 14, 740.	3.7	5
3	Impact of positive surgical margin length and Gleason grade at the margin on oncologic outcomes in patients with nonorganâ€confined prostate cancer. Prostate, 2022, 82, 949-956.	2.3	3
4	Oncologic outcomes of organ-confined Gleason grade group 4-5 prostate cancer after radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 161.e9-161.e14.	1.6	3
5	Regression Discontinuity Analysis of Salvage Radiotherapy in Prostate Cancer. European Urology Oncology, 2021, 4, 817-820.	5.4	1
6	Combined systematic versus stand-alone multiparametric MRI-guided targeted fusion biopsy: nomogram prediction of non-organ-confined prostate cancer. World Journal of Urology, 2021, 39, 81-88.	2.2	11
7	Assessing the Outcome of Holmium Laser Enucleation of the Prostate by Age, Prostate Volume, and a History of Blood Thinning Agents: Report from a Single-Center Series of >1800 Consecutive Cases. Journal of Endourology, 2021, 35, 639-646.	2.1	20
8	The Role of Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography in the Primary Staging of Newly Diagnosed Prostate Cancer: A Systematic Review of the Literature. European Urology Oncology, 2021, 4, 370-395.	5.4	25
9	Association of neurovascular bundle preservation with oncological outcomes in patients with high-risk prostate cancer. Prostate Cancer and Prostatic Diseases, 2021, 24, 193-201.	3.9	7
10	Impact of Age on Perioperative Outcomes at Radical Prostatectomy: A Population-Based Study. European Urology Focus, 2020, 6, 1213-1219.	3.1	5
11	The Impact of Anxiety and Depression on Surgical and Functional Outcomes in Patients Who Underwent Radical Prostatectomy. European Urology Focus, 2020, 6, 1199-1204.	3.1	25
12	Tumor characteristics, oncological and functional outcomes after radical prostatectomy in very young men â‰ <b>≋</b> €‰45Âyears of age. World Journal of Urology, 2020, 38, 95-101.	2.2	8
13	Effect of bladder neck sparing at robot-assisted laparoscopic prostatectomy on postoperative continence rates and biochemical recurrence. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 1.e11-1.e16.	1.6	3
14	Retrograde ejaculation after holmium laser enucleation of the prostate (HoLEP)â€"Impact on sexual function and evaluation of patient bother using validated questionnaires. Andrology, 2020, 8, 1779-1786.	3.5	13
15	Validation of the updated eighth edition of AJCC for prostate cancer: Removal of pT2 substages – Does extent of tumor involvement matter?. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 637.e1-637.e7.	1.6	1
16	Validation of the Social Security Administration Life Tables (2004–2014) in Localized Prostate Cancer Patients within the Surveillance, Epidemiology, and End Results database. European Urology Focus, 2019, 5, 807-814.	3.1	22
17	Inverse stage migration patterns in North American patients undergoing local prostate cancer treatment: a contemporary population-based update in light of the 2012 USPSTF recommendations. World Journal of Urology, 2019, 37, 469-479.	2.2	25
18	Impact of positive surgical margin length and Gleason grade at the margin on biochemical recurrence in patients with organâ€confined prostate cancer. Prostate, 2019, 79, 1832-1836.	2.3	38

#	Article	IF	Citations
19	Prostate cancer prognosis in men with other malignancies prior to radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 575.e1-575.e7.	1.6	4
20	Impact of the estimated blood loss during radical prostatectomy on functional outcomes. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 298.e11-298.e17.	1.6	7
21	External Validation of the European Association of Urology Biochemical Recurrence Risk Groups to Predict Metastasis and Mortality After Radical Prostatectomy in a European Cohort. European Urology, 2019, 75, 896-900.	1.9	74
22	Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes. European Urology, 2019, 76, 106-114.	1.9	77
23	The Impact of Lymph Node Metastases Burden at Radical Prostatectomy. European Urology Focus, 2019, 5, 399-406.	3.1	19
24	Are the Results of the Prostate Testing for Cancer and Treatment Trial Applicable to Contemporary Prostate Cancer Patients Treated with Radical Prostatectomy? Results from Two High-volume European Institutions. European Urology Focus, 2019, 5, 545-549.	3.1	5
25	Assessment of Oncological Outcomes After Radical Prostatectomy According to Preoperative and Postoperative Cancer of the Prostate Risk Assessment Scores: Results from a Large, Two-center Experience. European Urology Focus, 2019, 5, 568-576.	3.1	5
26	Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion. Prostate, 2018, 78, 469-475.	2.3	40
27	Contemporary approach to predict early biochemical recurrence after radical prostatectomy: update of the Walz nomogram. Prostate Cancer and Prostatic Diseases, 2018, 21, 386-393.	3.9	11
28	Validation of the current eligibility criteria for focal therapy in men with localized prostate cancer and the role of MRI. World Journal of Urology, 2018, 36, 705-712.	2.2	5
29	Survival benefit of local versus no local treatment for metastatic prostate cancerâ€"Impact of baseline PSA and metastatic substages. Prostate, 2018, 78, 753-757.	2.3	27
30	Local treatment for metastatic prostate cancer: A systematic review. International Journal of Urology, 2018, 25, 390-403.	1.0	37
31	Longâ€term cancer control outcomes in patients with biochemical recurrence and the impact of time from radical prostatectomy to biochemical recurrence. Prostate, 2018, 78, 676-681.	2.3	23
32	Adjuvant Therapies in Nonmetastatic Renal-Cell Carcinoma: A Review of the Literature. Clinical Genitourinary Cancer, 2018, 16, 176-183.	1.9	16
33	Tumor characteristics, treatments, and oncological outcomes of prostate cancer in men aged â‰50 years: a population-based study. Prostate Cancer and Prostatic Diseases, 2018, 21, 71-77.	3.9	13
34	Adherence to pelvic lymph node dissection recommendations according to the National Comprehensive Cancer Network pelvic lymph node dissection guideline and the D'Amico lymph node invasion risk stratification. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 81.e17-81.e24.	1.6	18
35	The impact of time to catheter removal on short-, intermediate- and long-term urinary continence after radical prostatectomy. World Journal of Urology, 2018, 36, 1247-1253.	2.2	16
36	Does surgical delay for radical prostatectomy affect biochemical recurrence? A retrospective analysis from a Canadian cohort. World Journal of Urology, 2018, 36, 1-6.	2.2	20

3

#	Article	IF	Citations
37	Radical prostatectomy or radiotherapy reduce prostate cancer mortality in elderly patients: a population-based propensity score adjusted analysis. World Journal of Urology, 2018, 36, 7-13.	2.2	23
38	Effect of pathological high-risk features on cancer-specific mortality in non-metastatic clear cell renal cell carcinoma: a tool for optimizing patient selection for adjuvant therapy. World Journal of Urology, 2018, 36, 51-57.	2.2	16
39	The impact of lymph node dissection and positive lymph nodes on cancerâ€specific mortality in contemporary <scp>pT</scp> <sub>2â€3</sub> nonâ€metastatic renal cell carcinoma treated with radical nephrectomy. BJU International, 2018, 121, 383-392.	2.5	30
40	Comparison of 11 Active Surveillance Protocols in Contemporary European Men Treated With Radical Prostatectomy. Clinical Genitourinary Cancer, 2018, 16, e141-e149.	1.9	10
41	First North American validation and headâ€toâ€head comparison of four preoperative nomograms for prediction of lymph node invasion before radical prostatectomy. BJU International, 2018, 121, 592-599.	2.5	32
42	Improved cancer-specific free survival and overall free survival in contemporary metastatic prostate cancer patients: a population-based study. International Urology and Nephrology, 2018, 50, 71-78.	1.4	37
43	Radical prostatectomy after previous TUR-P: Oncological, surgical, and functional outcomes. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 527.e21-527.e28.	1.6	16
44	Up regulation of the steroid hormone synthesis regulator HSD3B2 is linked to early PSA recurrence in prostate cancer. Experimental and Molecular Pathology, 2018, 105, 50-56.	2.1	6
45	Increase in the Annual Rate of Newly Diagnosed Metastatic Prostate Cancer: A Contemporary Analysis of the Surveillance, Epidemiology and End Results Database. European Urology Oncology, 2018, 1, 314-320.	5.4	19
46	The effect of age on cancer-specific mortality in patients with small renal masses: A population-based analysis. Canadian Urological Association Journal, 2018, 12, E325-30.	0.6	13
47	Trend of Adverse Stage Migration in Patients Treated with Radical Prostatectomy for Localized Prostate Cancer. European Urology Oncology, 2018, 1, 160-168.	5.4	15
48	Postoperative complications of contemporary open and robotâ€assisted laparoscopic radical prostatectomy using standardised reporting systems. BJU International, 2018, 122, 801-807.	2.5	52
49	External validation of the novel International Society of Urological Pathology (ISUP) Gleason grading groups in a large contemporary Canadian cohort. Canadian Urological Association Journal, 2018, 12, .	0.6	2
50	Population-Based Validation of the 2014 ISUP Gleason Grade Groups in Patients Treated With Radical Prostatectomy, Brachytherapy, External Beam Radiation, or no Local Treatment. Prostate, 2017, 77, 686-693.	2.3	33
51	Oncologic and Functional Outcomes after Radical Prostatectomy for High or Very High Risk Prostate Cancer: European Validation of the Current NCCN® Guideline. Journal of Urology, 2017, 198, 354-361.	0.4	36
52	Radical prostatectomy neutralizes obesity-driven risk of prostate cancer progression. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 243-249.	1.6	11
53	External Beam Radiotherapy Affects Serum Testosterone in Patients with Localized Prostate Cancer. Journal of Sexual Medicine, 2017, 14, 876-882.	0.6	16
54	Long-term oncological outcomes in patients with limited nodal disease undergoing radical prostatectomy and pelvic lymph node dissection without adjuvant treatment. World Journal of Urology, 2017, 35, 1833-1839.	2.2	17

#	Article	IF	CITATIONS
55	Marital status and gender affect stage, tumor grade, treatment type and cancer specific mortality in T1 $\hat{a}$ $\in$ "2 N0 M0 renal cell carcinoma. World Journal of Urology, 2017, 35, 1899-1905.	2.2	28
56	Short- and Long-term Functional Outcomes and Quality of Life after Radical Prostatectomy: Patient-reported Outcomes from a Tertiary High-volume Center. European Urology Focus, 2017, 3, 615-620.	3.1	44
57	Survival of metastatic renal cell carcinoma patients continues to improve over time, even in targeted therapy era. International Urology and Nephrology, 2017, 49, 2143-2149.	1.4	36
58	Functional Outcomes and Quality of Life After Radical Prostatectomy Only Versus a Combination of Prostatectomy with Radiation and Hormonal Therapy. European Urology, 2017, 71, 330-336.	1.9	57
59	Complications after salvage radical prostatectomy: vesicourethral anastomosis leaks and possible prevention. Translational Andrology and Urology, 2017, 6, 994-996.	1.4	1
60	Oncological, functional and perioperative outcomes in transplant patients after radical prostatectomy. World Journal of Urology, 2016, 34, 1101-1105.	2.2	10